WO2000027819A2 - Anthranilsäureamide und deren verwendung als arzneimittel - Google Patents
Anthranilsäureamide und deren verwendung als arzneimittel Download PDFInfo
- Publication number
- WO2000027819A2 WO2000027819A2 PCT/EP1999/008478 EP9908478W WO0027819A2 WO 2000027819 A2 WO2000027819 A2 WO 2000027819A2 EP 9908478 W EP9908478 W EP 9908478W WO 0027819 A2 WO0027819 A2 WO 0027819A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- stands
- hydrogen
- halogen
- methyl
- Prior art date
Links
- 0 *N(c1ccccc1C(O1)=O)C1=O Chemical compound *N(c1ccccc1C(O1)=O)C1=O 0.000 description 2
- VHVCBKQJCOKLTD-UHFFFAOYSA-N CN(c1nc(Br)c(cccc2)c2c1)c1c(cccc2)c2cc(N)n1 Chemical compound CN(c1nc(Br)c(cccc2)c2c1)c1c(cccc2)c2cc(N)n1 VHVCBKQJCOKLTD-UHFFFAOYSA-N 0.000 description 1
- UAUJZFNYIBXEDG-UHFFFAOYSA-N C[n](cc1)c(cc2)c1cc2Cl Chemical compound C[n](cc1)c(cc2)c1cc2Cl UAUJZFNYIBXEDG-UHFFFAOYSA-N 0.000 description 1
- CSUGQXMRKOKBFI-UHFFFAOYSA-N C[n]1ncc2c1cccc2 Chemical compound C[n]1ncc2c1cccc2 CSUGQXMRKOKBFI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the invention relates to anthranilic acid amides and their use as medicaments for the treatment of diseases caused by persistent
- Angiogenesis are triggered as well as their intermediates for the production of the anthranilic acid amides.
- Persistent angiogenesis can be the cause of various diseases such as psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombogenic microangiopathic syndrome, transplant rejections and glomerulopathy, fibrotic Diseases such as cirrhosis of the liver, mesangial cell proliferative diseases and
- Direct or indirect inhibition of the VEGF receptor can be used to treat such diseases and other VEGF-induced pathological angiogenesis and vascular permeable conditions such as tumor vascularization.
- VEGF-induced pathological angiogenesis and vascular permeable conditions such as tumor vascularization.
- the growth of tumors can be inhibited by soluble receptors and antibodies against VEGF.
- Persistent angiogenesis is induced by the factor VEGF via its receptor.
- VEGF binds to the receptor and that tyrosine phosphorylation is caused.
- Phenylanthranilamide derivatives are already known which are used as angiotensin antagonists (EP 564 356) and as anti-inflammatories and anti-ulcer compounds (U.S. 3,409,668).
- C ⁇ alkyl or the group NR 10 and / or R a and or R b with R c and or R d or
- R c can form a bond with R e and or R f , or up to two of the radicals R a -R f one
- Y stands for the group - (CH 2 ) P ,
- R 1 for unsubstituted or optionally mono- or polysubstituted with halogen, C ⁇ -alkyl, mono- or polysubstituted with halogen
- R 2 represents hydrogen or C ⁇ alkyl or with
- R a -R f from Z or to R, a bridge with up to
- R 3 for unsubstituted or optionally one or more times with halogen, C ⁇ -alkyl, C ⁇ -
- R 4 , R 5 , R 6 and R 7 independently of one another for hydrogen
- R 8 , R 9 and R 10 are independently hydrogen or
- C ⁇ alkyl mean, and their isomers and salts, stop tyrosine phosphorylation or persistent angiogenesis and thus the growth and spread of
- R 2 forms a bridge to R 1 , heterocycles are formed to which R 1 is fused. Examples include:
- R a , R b , R c , R d , R e , R f independently represent hydrogen or C 1 -C 6 alkyl, Z forms an alkyl chain.
- R a and / or R b form a bond with R c and / or R d or R c and / or R d with R e and / or R f , then Z stands for an alkenyl or alkynyl chain.
- Z represents a cycloalkyl or cycloalkenyl group.
- R a -R f form a bridge with up to 3 C atoms to R 1 , then Z together with R 1 is a benzo or hetaryl-fused (Ar) cycloalkyl. Examples include:
- Examples include:
- alkyl is in each case a straight-chain or branched alkyl radical, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. To understand butyl, pentyl, isopentyl or hexyl, C 4 -C 4 -alkyl radicals being preferred.
- Cycloalkyl is understood to mean cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
- Cycloalkenyl is to be understood in each case as cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, it being possible for the linkage to take place both on the double bond and on the single bonds.
- Halogen is to be understood as fluorine, chlorine, bromine or iodine.
- alkenyl and alkynyl substituents are each straight-chain or branched and contain 2-6, preferably 2-4 carbon atoms.
- the following radicals may be mentioned, for example: vinyl, propen-1-yl, propen-2-yl, but-1-en-1-yl, but-1-en-2-yl, but-2-en-1-yl , But-2-en-2-yl, 2-methyl-prop-2-en-1-yl, 2-methyl-prop-1-en-1-yl, but-1-en-3-yl, ethynyl , Prop-1-in-1-yl, BuM-in-1-yl, But-2-in-1-yl, But-3-en-1-yl, allyl.
- the aryl radical has 6 to 12 carbon atoms such as naphthyl, biphenyl and especially phenyl.
- the heteroaryl radical can be benzo-condensed in each case.
- Examples include 5-ring heteroaromatics: thiophene, furan, oxazole, thiazole, imidazole, pyrazole and benzode vate thereof, and 6-ring heteroaromatics pyridine, pyrimidine, triazine, quinoline, isoquinoline and benzodehvate, with benzo-fused heteroaryl residues binding both to Heterocycle as well as on the benzo ring.
- aryl and heteroaryl radicals can each be substituted 1-, 2- or 3-fold, identically or differently, with halogen, C ⁇ _4-alkoxy, nitro, trifluoromethyl, trifluoromethoxy, cyano, SO q R 5 or C-alkyl, where q is 0 - 2 stands.
- the physiologically compatible salts of organic and inorganic bases are suitable as salts, for example the readily soluble alkali and alkaline earth metal salts and N-methylglucamine, dimethylglucamine, ethylglucamine, lysine, 1, 6-hexadiamine, ethanolamine , Glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane, aminopropanediol, Sovak base, 1-amino-2,3,4-butanetriol.
- physiologically compatible salts of organic and inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, tartaric acid and others are suitable.
- R a R_> Rc Rd 'Re' f independently of one another for hydrogen
- Y stands for the group - (CH 2 ) P ,
- R 1 represents phenyl, pyridyl, 5-chloro-2,3-
- R 2 represents hydrogen or C ⁇ alkyl or with
- R a -R f from Z or to R forms a bridge with up to 3 ring members, R 3 for unsubstituted or optionally mono- or polysubstituted with halogen C ⁇ alkyl, C ⁇ - alkoxy or hydroxy, monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl,
- R 4 , R 5 , R 6 and R 7 independently of one another for hydrogen
- R 8 , R 9 and R 10 independently of one another for hydrogen or
- C ⁇ alkyl mean, and their isomers and salts.
- Y stands for the group -CH 2 -
- R 1 is phenyl, pyridyl, 5-chloro-2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-1H-indol-3-yl, naphthyl, 1, 2,3,4-tetrahydronaphthyl, Benzo-1, 2,5-oxadiazole, 6,7-dimethoxy-1, 2,3,4-tetrahydro-2-naphthyl, or for one or more times with C 1 -C 4 alkyl, C 1 -C 4 -Alkoxy, hydroxy, halogen, trifluoromethyl substituted phenyl or pyridyl or for the group
- R 2 represents hydrogen or methyl
- R 3 represents pyridyl or phenyl, pyridyl or 1, 2,3,4-tetrahydronaphthyl or the group substituted by hydroxy, halogen, methyl or methoxy
- R 5 and R 6 independently of one another for hydrogen
- R 4 and R 7 are independently hydrogen or
- R 9 represents hydrogen
- R 10 represents hydrogen or methyl, and their isomers and salts.
- Y stands for the group -CH 2 -
- R 1 is phenyl, pyridyl, 5-chloro-2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-1H-indol-3-yl, naphthyl, 1, 2,3,4-tetrahydronaphthyi, benzo -1, 2,5-oxadiazole or 6,7-dimethoxy-1, 2,3,4-tetrahydro-2-naphthyl or for one or more with CC 4 alkyl, CC 4 alkoxy, hydroxy, halogen, trifluoromethyl , substituted phenyl or pyridyl or for the group
- R 2 represents hydrogen or methyl
- R 3 represents pyridyl or phenyl, pyridyl or 1, 2,3,4-tetrahydronaphthyl substituted by one or more hydroxyl, halogen, methyl or methoxy groups, or the group ⁇
- R 5 and R 6 independently of one another represent hydrogen
- Halogen, methyl, methoxy or trifluoromethyl, R 4 and R 7 independently of one another are hydrogen and
- R 9 is hydrogen
- R 10 represents hydrogen or methyl, and their isomers and salts.
- W stands for sulfur
- Y represents the group -CH 2 -
- R 1 represents phenyl, pyridyl, 5-chloro-2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-1 H-indol-3-yl, naphthyl, 1, 2,3,4-tetrahydronaphthyl, benzo-1, 2,5-oxadiazole or 6,7-dimethoxy-1, 2,3,4-tetrahydro-2-naphthyl or for one or more times with C ⁇ O, - Alkyl, CC 4 alkoxy, hydroxy, halogen, trifluoromethyl, substituted phenyl or Pyridyl or for the group
- R 2 represents hydrogen or methyl
- R 3 represents pyridyl or phenyl, pyridyl or 1, 2,3,4-tetrahydronaphthyl substituted by one or more hydroxyl, halogen, methyl or methoxy groups, or the group
- R 5 and R 6 independently of one another for hydrogen
- R 4 and R 7 are independently hydrogen and
- R 9 represents hydrogen
- R 10 represents hydrogen or methyl, and their isomers and salts.
- W represents two hydrogen atoms
- Y stands for the group -CH 2 -
- R 1 is phenyl, pyridyl, 5-chloro-2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-1H-indol-3-yl, naphthyl, 1, 2,3,4-tetrahydronaphthyl, benzo -1, 2,5-oxadiazole or 6,7-dimethoxy-1, 2,3,4-tetrahydro-2-naphthyl or for one or more with CC 4 - alkyl, CC 4 alkoxy, hydroxy, halogen, trifluoromethyl , substituted phenyl or pyridyl or for the group
- R 2 represents hydrogen or methyl
- R 3 represents pyridyl or phenyl, pyridyl or 1, 2,3,4-tetrahydronaphthyl substituted by one or more hydroxyl, halogen, methyl or methoxy groups, or the group
- R 4 and R 7 independently of one another represent hydrogen
- Halogen, methyl, methoxy or trifluoromethyl, R 5 and R 6 are independently hydrogen and
- R 9 is hydrogen
- R 10 represents hydrogen or methyl, and their isomers and salts.
- the compounds of the invention prevent phosphoryiation, i.e. H. certain tyrosine kinases can be selectively inhibited, whereby persistent angiogenesis can be stopped. This prevents the growth and spread of tumors, for example.
- the compounds of general formula I according to the invention also include the possible tautomeric forms and include the E or Z isomers or, if a chiral center is present, also the racemates and enantiomers.
- the compounds of the formula I and their physiologically tolerable salts can be used as medicaments on account of their inhibitory activity with regard to phosphorylation of the VEGF receptor. Because of their activity profile, the compounds according to the invention are suitable for the treatment of
- the compounds of the formula I are identified as inhibitors of the tyrosine kinase KDR and FLT, they are particularly suitable for the treatment of diseases which are caused by the persistent angiogenesis triggered by the VEGF receptor or an increase in vascular permeability.
- the present invention also relates to the use of the compounds according to the invention as inhibitors of the tyrosine kinase KDR and FLT.
- the present invention thus also relates to medicaments for the treatment of tumors.
- the compounds according to the invention can be used either alone or in formulations as medicaments for the treatment of psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofribroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosic syndrome, malignant nephrosic syndrome, Transplant rejection and glomerulopathy, fibrotic diseases such as cirrhosis of the liver, mesangial cell proliferative diseases, atherosclerosis and injuries to the nerve tissue are used.
- arthritis such as rheumatoid arthritis, hemangioma, angiofribroma
- eye diseases such as diabetic retinopathy, neovascular glaucoma
- kidney diseases such as glomerulonephritis, diabetic nephropathy, malignant nephrosic
- the compounds of the invention can also be used to inhibit the reocclusion of vessels after balloon catheter treatment. lung, in vascular prosthetics or after the insertion of mechanical devices to keep vessels open, such as. B. Stents.
- VEGF-related edema can also be suppressed.
- the invention further relates to the use of the compounds of the general formula I for the manufacture of a medicament for the treatment of tumors, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofribroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma,
- Kidney diseases such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopatic syndromes, transplant rejection and glomerulopathy, fibrotic diseases such as cirrhosis of the liver, mesangial cell proliferative diseases, atherosclerosis, injuries of the nerve tissue, inhibition of ballon, or inhibition of the therapy after reclamation after reocclusion after reocclusion mechanical devices to keep open vessels such.
- B. Stents such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopatic syndromes, transplant rejection and glomerulopathy
- fibrotic diseases such as cirrhosis of the liver, mesangial cell proliferative diseases, atherosclerosis, injuries of the nerve tissue, inhibition of ballon, or inhibition of the therapy after reclamation after reocclusion after reocclusion mechanical devices to keep open vessels such.
- a pharmaceutical preparation which, in addition to the active ingredient for enteral or parenteral administration, has suitable pharmaceutical, organic or inorganic inert carrier materials, such as, for example, water, gelatin, gum arabic, milk sugar , Starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
- suitable pharmaceutical, organic or inorganic inert carrier materials such as, for example, water, gelatin, gum arabic, milk sugar , Starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
- the pharmaceutical preparations can be in solid form, for example as tablets, dragees, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions. If necessary, they also contain auxiliary substances such as preservatives, stabilizers, wetting agents or emulsifiers, salts for changing the osmotic pressure or buffers.
- Injection solutions or suspensions in particular aqueous solutions of the active compounds in polyhydroxyethoxylated castor oil, are particularly suitable for parenteral use.
- Surfactant auxiliaries such as salts of bile acids or animal or vegetable phospholipids, but also mixtures thereof and liposomes or their components can also be used as carrier systems.
- Lactose corn or potato starch, suitable. It can also be used in liquid form, for example as juice, to which a sweetener may be added.
- the dosage of the active ingredients can vary depending on the route of administration, age and
- the daily dose is 0.5-1000 mg, preferably 50-200 mg, and the dose can be given as a single dose to be administered once or divided into 2 or more daily doses.
- R 4 to R? have the above meaning and TH or a protective group and A is halogen or OR 13 , where R 13 denotes a hydrogen atom, C 1-4 alkyl or C 1-4 acyl or closes a ring with T, first alkylates N and then converts COA to an amide and then optionally splitting off protective groups or first converting them into that amide and then N-alkylating or b) orthometallized a compound of the formula III in which R 4 to 7 have the meaning given above and TH or a protective group and then intercepting them with an electrophile Transferred amide, then cleaves the protecting group and alkylates the amino group, or
- R 4 to R? have the above meaning and mean TH or a protective group and B halogen or O-triflate, O-tosylate or O-mesylate converted into an amide, then the protective group is split off and the amino group is alkylated
- the amide formation takes place according to methods known from the literature.
- An appropriate ester can be used to form the amide.
- the ester is reacted with aluminum trimethyl and the corresponding amine in solvents such as toluene at temperatures from 0 ° C. to the boiling point of the solvent.
- solvents such as toluene at temperatures from 0 ° C. to the boiling point of the solvent.
- This method can also be used for unprotected anthranilic acid esters. If the molecule contains two ester groups, both are converted into the same amide.
- amidines are obtained under analogous conditions.
- amide formation all methods known from peptide chemistry are also available for amide formation.
- aprotic polar solvents such as dimethylformamide
- an activated acid derivative for example obtainable with hydroxybenzotriazole and a carbodiimide such as diisopropylcarbodiimide or with pre-formed reagents such as HATU (Chem. Comm. 1994, 201) or BTU , at temperatures between 0 ° C and the boiling point of the
- Solvent preferably at 80 ° C with the amine at HATU preferably at room temperature. These methods are also with the to use unprotected anthranilic acids.
- the process using the mixed acid anhydride, imidazolide or azide can also be used for the amide formation. Prior protection of the amino group, for example as an amide, is not necessary in all cases, but can have a favorable effect on the reaction.
- a special starting material is isatoic anhydrides, in which the protection of the amino group and the activation of the acid function are present at the same time.
- the ortho position can be metallized by reaction with organometallic compounds such as n-butyllithium and then trapped with isocyanates or isothiocyanates to form the anthranilamides or anthranilthioamides.
- organometallic compounds such as n-butyllithium
- isocyanates or isothiocyanates to form the anthranilamides or anthranilthioamides.
- a bromine or iodine substituent in this ortho position facilitates the ortho metallation by means of shark metal exchange.
- Suitable solvents are ethers such as diethyl ether or tetrahydrofuran or hydrocarbons such as hexane, but also mixtures thereof.
- complexing agents such as tetramethylethylene diamine (TMEDA) is advantageous.
- the temperatures range between -78 ° C and room temperature.
- the BOC amides are cleaved by treatment with acids such as trifluoroacetic acid without solvent or in solvents such as methylene chloride at temperatures from 0 ° C. to the boiling point of the solvent or with aqueous hydrochloric acid, preferably 1 N hydrochloric acid in solvents such as ethanol or dioxane at temperatures from room temperature to the boiling point of the solvent.
- acids such as trifluoroacetic acid without solvent or in solvents such as methylene chloride at temperatures from 0 ° C. to the boiling point of the solvent or with aqueous hydrochloric acid, preferably 1 N hydrochloric acid in solvents such as ethanol or dioxane at temperatures from room temperature to the boiling point of the solvent.
- the amide group can also be introduced by carbonation.
- the corresponding compounds of the formula IV o-iodo-, o-bromo- or o-triflyloxyanilines
- carbon monoxide at normal or elevated pressure and with an amine in the presence of
- Transition metal catalysts such as palladium (II) chloride or palladium (II) acetate or palladium tetrakistriphenylphosphine in ⁇
- Solvents such as dimethylformamide are implemented.
- a ligand such as triphenylphosphine and the addition of a base such as tributylamine can be advantageous. (see for example J. Org. Chem. 1974, 3327; J. Org. Chem. 1996, 7482; Synth. Comm. 1997, 367; Tetr.Lett 1998, 2835)
- the second ester group for example, must be introduced into the molecule after the first amide group has been generated and then amidated, or one molecule has one group as an ester, the other as an acid and amidates the two groups successively according to different methods.
- Thioamides are derived from the anthranilamides by reaction with diphosphadithians according to Bull Soc.Chim.Belg. 87, 229, 1978 or by reaction with phosphorus pentasulfide in solvents such as pyridine or without solvents at temperatures from 0 ° C. to 200 ° C. .
- the products can also be subjected to electrophilic aromatic substitutions.
- the substitution then takes place in the ortho or para position to the or one of the amino group (s).
- Friedel-Crafts acylation with acid chlorides in the presence of Friedel-Crafts catalysts such as aluminum trichloride in solvents such as nitromethane, carbon disulfide, methylene chloride or nitrobenzene at temperatures between 0 ° C and the boiling point of the solvent can preferably be acylated at room temperature.
- one or more nitro groups can be introduced in polar solvents such as ethanol or glacial acetic acid or also in acetic anhydride, for example by nitrating acid, variously concentrated nitric acid without solvent or by metal nitrates such as copper (II) nitrate or iron (III) nitrate.
- Halogens are introduced by processes known from the literature, for example by reaction with bromine, N-bromo- or N-iodosuccinimide or urotropin hydrotribromide in polar solvents such as tetrahydrofuran, acetonitrile, methylene chloride, glacial acetic acid or dimethylformamide.
- the reduction of the nitro group is carried out in polar solvents at room temperature or elevated temperature.
- Suitable catalysts for the reduction are metals such as Raney nickel or noble metal catalysts such as palladium or platinum or also palladium hydroxide, optionally on supports.
- metals such as Raney nickel or noble metal catalysts such as palladium or platinum or also palladium hydroxide, optionally on supports.
- hydrogen ammonium formate, cyclohexene or hydrazine, for example, can also be used in a known manner.
- Reducing agents such as tin-II-chloride or titanium - ([li) -chloride can be used as well as complex metal hydrides possibly in the presence of heavy metal salts. Iron can also be used as a reducing agent.
- the reaction is then carried out in the presence of an acid such as e.g. Acetic acid or ammonium chloride optionally carried out with the addition of a solvent such as water, methanol, etc. With an
- alkylation can be carried out by customary methods - for example using alkyl halides - or using the Mitsunobu variant by reaction with an alcohol in the presence of, for example, triphenylphosphine and azodicarboxylic acid esters.
- the amine can also be subjected to a reductive alkylation with aldehydes or ketones, the reaction being carried out in the presence of a reducing agent such as sodium cyanoborohydride in a suitable inert solvent such as ethanol at temperatures from 0 ° C. to the boiling point of the solvent.
- the Schiff base may be advantageous to first form the Schiff base by reacting the aldehyde with the amine in solvents such as ethanol or methanol, optionally with the addition of auxiliaries such as glacial acetic acid, and only then reducing agents such as. B. add sodium cyanoborohydride.
- the hydrogenation of alkene or alkyne groups in the molecule is carried out in the usual way, for example by catalytically excited hydrogen.
- Heavy metals such as palladium or platinum, optionally on a support or Raney nickel, can be used as catalysts.
- Alcohols such as e.g. Ethanol in question.
- the process is carried out at temperatures from 0 ° C. to the boiling point of the solvent and at pressures up to 20 bar, but preferably at room temperature and normal pressure.
- catalysts such as a Lindlar catalyst, triple bonds can be partially hydrogenated to double bonds, the Z form preferably being formed.
- acylation of an amino group is carried out in a customary manner, for example using an acid halide or acid anhydride, optionally in the presence of a base such as dimethylaminopyridine in solvents such as methylene chloride, tetrahydrofuran or pyridine, according to the Schotten-Baumann variant in aqueous solution at a weakly alkaline pH or by reaction with an anhydride in glacial acetic acid.
- a base such as dimethylaminopyridine
- solvents such as methylene chloride, tetrahydrofuran or pyridine
- the introduction of the halogens chlorine, bromine, iodine or the azido group via an amino group can also be carried out, for example, according to Sandmeyer, by reacting the diazonium salts formed intermediately with nitrites with copper (l) chloride or copper (l) bromide in the presence of the corresponding acid such as hydrochloric acid or Hydrobromic acid or reacted with potassium iodide. If an organic nitrous acid ester is used, the halogens can be introduced, for example, by adding methylene iodide or tetrabromomethane in a solvent such as dimethylformamide.
- the removal of the amino group can be accomplished either by reaction with an organic nitric acid ester in tetrahydrofuran or by diazotization and reductive boiling of the diazonium salt, for example with phosphorous acid, optionally with the addition of copper (I) oxide.
- Fluorine can be introduced, for example, by the Balz-Schiemann reaction of diazonium tetrafluoroborate or by J. Fluor. Chem. 76, 1996, 59-62 by diazotization in the presence of HFxPyridin and subsequent boiling, if necessary in the presence of a fluoride ion source such as e.g. Tetrabutylammonium fluoride.
- a fluoride ion source such as e.g. Tetrabutylammonium fluoride.
- the azido group can be introduced after diazotization by reaction with sodium azide at room temperature.
- Ether cleavages are carried out according to methods customary in the literature. Selective cleavage can also be achieved with several groups present in the molecule.
- the ether is treated, for example, with boron tribromide in solvents such as dichloromethane at temperatures between -100 ° C to the boiling point of the solvent, preferably at -78 ° C.
- solvents such as dichloromethane
- the temperature can preferably be between 150 ° C. and between room temperature and the boiling point of the solvent.
- N- or O-alkylation of amides such as pyrid-2-one or 2-hydroxypyridine is achieved using methods known from the literature.
- bases such as sodium hydride or potassium carbonate in solvents such as dimethylformamide and alkylation with alkyl halides such as methyl iodide
- alkyl halides such as methyl iodide
- an O-alkylation is also obtained in the reaction with inert trialkyloxonium tetrafluoroborate
- Solvents such as methylene chloride.
- the methods enable a selective alkylation of the pyridone compared to the benzoic acid amide.
- the isomer mixtures can be separated into the enantiomers or E / Z isomers by customary methods such as, for example, crystallization, chromatography or salt formation.
- the salts are prepared in the customary manner by adding a solution of the compound of the formula I with the equivalent amount or an excess of a base or acid, which is optionally in solution, and removing the precipitate or working up the solution in the customary manner.
- the present invention also relates to the isatoic acid derivatives of the general formula V.
- Y stands for the group -CH 2 -
- R 3 is pyridyl or phenyl substituted by hydroxyl, bromine, methyl or methoxy or 1, 2,3,4-
- R 5 and R 6 are hydrogen, chlorine, methyl, methoxy or
- R 4 and R 7 are hydrogen, RR a9 is hydrogen, and their isomers and salts.
- the intermediates are partially active themselves and can thus also be used to produce a medicament for the treatment of tumors, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofribroma, eye diseases, such as diabetic retinopathy, neovascuiar glaucoma, kidney diseases, such as glomerulonephritis, diabetic malignant nephropatia , thrombic microangiopatic syndromes, transplant rejection and glomerulopathy, fibrotic diseases such as cirrhosis of the liver, mesangial cell proliferative diseases, atherosclerosis, injuries to the nerve tissue, inhibition of reocciusion of vessels after balloon catheter treatment, in the case of vascular prosthesis or after the insertion of mechanical devices, such as after the insertion of mechanical devices, for the insertion of mechanical devices.
- a mixture of 7.5 g of methyl anthranilate and 8.6 g of pyridine-4-carbaldehyde in 300 ml of methanol is mixed with 3 ml of acetic acid under a nitrogen atmosphere and stirred for 12 hours at room temperature.
- the reaction mixture is then mixed with 5.7 g of sodium cyanoborohydride (85%) and stirred for a further 3 hours at room temperature. After this time, another 14.1 g of sodium cyanoborohydride (85%) are added and the mixture is stirred for a further 12 hours at room temperature.
- the reaction mixture is concentrated. The residue is taken up in ethyl acetate and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution. The dried organic phase is evaporated and the residue is purified by column chromatography on silica gel using hexane / ethyl acetate (1 +1).
- N- (4-pyridylmethyl) anthranilic acid are placed in 10 ml of dimethylformamide under argon and with the exclusion of moisture.
- 266 mg of 5-aminoindazole, 0.27 ml of methylmorpholine and 456 mg of 0- (7-azabenzotriazol-1-yl) -N, N, N ', N ' - tetramethyluronium hexafluorophosphate (HATU) are added.
- the mixture is then stirred for 4 hours at room temperature.
- dilute sodium hydrogen carbonate solution is added and the mixture is extracted three times with ethyl acetate.
- the combined organic phases are washed with water, dried, filtered and concentrated in vacuo. The residue is chromatographed on silica gel with ethyl acetate as the eluent.
- Stock solution A 3mM ATP in water pH 7.0 (-70 ° C)
- Stock solution B g-33P-ATP 1 mCi / 100 ⁇ l
- stock solution C poly- (Glu4Tyr) 10mg / ml in water
- Substrate solvent 10mM DTT, 10mM manganese chloride, 100mM magnesium chloride
- Enzyme solution 120mM Tris / HCl, pH 7.5, 10 ⁇ M sodium vanadium oxide
- Substrate solvent 10 ⁇ l inhibitor solution (substances corresponding to the dilutions, as a control 3% DMSO in substrate solvent) and 10 ⁇ l enzyme solution (11.25 ⁇ g enzyme stock solution (KDR or FLT-1 kinase) are diluted at 1.25 ° C. in 1.25 ml enzyme solution) . It is mixed thoroughly and incubated at room temperature for 10 minutes. Then add 10 ⁇ l stop solution (250mM EDTA, pH 7.0), mix and transfer 10 ⁇ l of the solution to a P 81 phosphocellulose filter. Then will 6> p
- IC50 values are determined from the inhibitor concentration which is necessary to inhibit phosphate incorporation to 50% of the uninhibited incorporation after deduction of the blank value (EDTA stopped reaction).
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA2001063917A UA71587C2 (uk) | 1998-11-10 | 1999-09-11 | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
PL99348349A PL348349A1 (en) | 1998-11-10 | 1999-11-09 | Antrhranilic acid amides and the use thereof as medicaments |
BR9915553-2A BR9915553A (pt) | 1998-11-10 | 1999-11-09 | Amidas de ácido antranìlico e seu emprego como medicamento |
JP2000580999A JP2002529452A (ja) | 1998-11-10 | 1999-11-09 | アントラニル酸アミド及び医薬剤としてのその使用 |
NZ511413A NZ511413A (en) | 1998-11-10 | 1999-11-09 | Antrhranilic acid amides and the use thereof as medicaments |
HU0104425A HUP0104425A3 (en) | 1998-11-10 | 1999-11-09 | Anthranilic acid amides and the use thereof for the treatment of angiogenesis |
EA200100524A EA004701B1 (ru) | 1998-11-10 | 1999-11-09 | Амиды антраниловой кислоты и их применение в качестве лекарственных средств |
AU10454/00A AU771180B2 (en) | 1998-11-10 | 1999-11-09 | Antrhranilic acid amides and the use thereof as medicaments |
EP99953967A EP1129074A2 (de) | 1998-11-10 | 1999-11-09 | Anthranilsäureamide und deren verwendung als arzneimittel |
CA002350208A CA2350208A1 (en) | 1998-11-10 | 1999-11-09 | Antrhranilic acid amides and the use thereof as medicaments |
EEP200100258A EE200100258A (et) | 1998-11-10 | 1999-11-09 | Antraniilhappe amiidid ja nende kasutamine ravimitena |
SK607-2001A SK6072001A3 (en) | 1998-11-10 | 1999-11-09 | Anthranilic acid amides and the use thereof as medicaments |
US09/831,506 US7122547B1 (en) | 1998-11-10 | 1999-11-09 | Anthranilic acid amides and the use thereof as medicaments |
NO20012245A NO320647B1 (no) | 1998-11-10 | 2001-05-07 | Anthranilsyreamider og anvendelse derav for fremstilling av medikamenter |
HK02103628A HK1041882A1 (en) | 1998-11-10 | 2002-05-14 | Anthranilic acid amides and their use in manufacturing pharmaceutical agents. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9824579.8A GB9824579D0 (en) | 1998-11-10 | 1998-11-10 | Organic compounds |
GB9824579.8 | 1998-11-10 | ||
DE19910396.8 | 1999-03-03 | ||
DE1999110396 DE19910396C2 (de) | 1999-03-03 | 1999-03-03 | Anthranilsäureamide und deren Verwendung als Arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000027819A2 true WO2000027819A2 (de) | 2000-05-18 |
WO2000027819A3 WO2000027819A3 (de) | 2000-08-17 |
Family
ID=26052266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/008478 WO2000027819A2 (de) | 1998-11-10 | 1999-11-09 | Anthranilsäureamide und deren verwendung als arzneimittel |
Country Status (23)
Cited By (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001085719A1 (de) * | 2000-05-09 | 2001-11-15 | Schering Aktiengesellschaft | Ortho substituierte anthranilsäureamide und deren verwendung als arzneimittel |
WO2001085671A2 (de) * | 2000-05-09 | 2001-11-15 | Schering Aktiengesellschaft | Anthranylamide und deren verwendung als arzneimittel |
WO2001097786A2 (en) * | 2000-06-21 | 2001-12-27 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
WO2002046181A2 (en) * | 2000-12-07 | 2002-06-13 | Cv Therapeutics, Inc. | Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
WO2002066470A1 (en) * | 2001-01-12 | 2002-08-29 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
WO2002090352A2 (de) * | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren |
WO2002090349A1 (de) * | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | N-oxidanthranylamid-derivate und deren verwendung als arzneimittel |
DE10123587A1 (de) * | 2001-05-08 | 2002-11-21 | Schering Ag | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel |
DE10123573A1 (de) * | 2001-05-08 | 2002-11-28 | Schering Ag | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel |
WO2002100833A1 (fr) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
WO2002055501A3 (en) * | 2001-01-12 | 2002-12-19 | Amgen Inc. | N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
WO2003000678A1 (de) * | 2001-05-08 | 2003-01-03 | Schering Aktiengesellschaft | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel |
WO2002068406A3 (en) * | 2001-01-12 | 2003-04-24 | Amgen Inc | Substituted amine derivatives and their use for the treatment of angiogenesis |
WO2004005279A2 (en) * | 2002-07-09 | 2004-01-15 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
WO2004007481A2 (en) * | 2002-07-17 | 2004-01-22 | Amgen Inc. | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
WO2004007458A1 (en) | 2002-07-17 | 2004-01-22 | Amgen Inc. | Substituted 2-alkylamine nicotinic amide derivatives and use there of |
EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
DE10235690A1 (de) * | 2002-07-31 | 2004-02-19 | Schering Ag | VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide |
WO2004050610A2 (en) * | 2002-12-04 | 2004-06-17 | Gene Logic Inc. | Modulators of melanocortin receptor |
WO2004063330A2 (en) | 2003-01-06 | 2004-07-29 | Osi Pharmaceuticals, Inc. | (2-carboxamido) (3-amino) thiophene compounds |
WO2004072069A1 (en) * | 2003-02-14 | 2004-08-26 | Glaxo Group Limited | Carboxamide derivatives |
WO2004078723A1 (ja) | 2003-03-07 | 2004-09-16 | Santen Pharmaceutical Co. Ltd. | 4-ピリジルアルキルチオ基を置換基として有する新規化合物 |
US6818661B2 (en) * | 2000-05-09 | 2004-11-16 | Novartis Ag | Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitors |
WO2004103306A2 (en) | 2003-05-19 | 2004-12-02 | Irm Llc | Immunosuppressant compounds and compositions |
WO2004108133A2 (en) * | 2003-06-05 | 2004-12-16 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
WO2004111005A1 (de) * | 2003-06-13 | 2004-12-23 | Schering Aktiengesellschaft | Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyridone |
WO2005000833A1 (en) | 2003-05-19 | 2005-01-06 | Irm, Llc | Immunosuppressant compounds and compositions |
WO2005004864A1 (en) * | 2003-07-11 | 2005-01-20 | Merck Patent Gmbh | Benzimidazole derivatives as raf kinase inhibitors |
WO2004069792A3 (en) * | 2003-02-03 | 2005-01-20 | Janssen Pharmaceutica Nv | Quinoline-derived amide modulators of vanilloid vr1 receptor |
US6864255B2 (en) | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
WO2005047273A1 (en) * | 2003-11-14 | 2005-05-26 | Novartis Ag | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors |
WO2005054179A2 (en) | 2003-12-03 | 2005-06-16 | Leo Pharma A/S | Hydroxamic acid esters and pharmaceutical use thereof |
EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
WO2005085202A1 (de) * | 2004-02-26 | 2005-09-15 | Merck Patent Gmbh | Pyridinamid-derivate als kinase-inhibitoren |
WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
WO2006047574A1 (en) | 2004-10-26 | 2006-05-04 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-amino) thiophene compounds |
US7087761B2 (en) | 2003-01-07 | 2006-08-08 | Hoffmann-La Roche Inc. | Cyclization process for substituted benzothiazole derivatives |
US7094789B2 (en) | 2002-07-22 | 2006-08-22 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivatives |
US7101868B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US7129245B2 (en) * | 1998-12-23 | 2006-10-31 | Eli Lilly And Company | Aromatic amides |
US7132438B2 (en) | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
CN1300113C (zh) * | 2001-11-08 | 2007-02-14 | 诺瓦提斯公司 | 邻氨基苯甲酰胺和其作为vegf受体酪氨酸激酶抑制剂的用途 |
WO2007038459A2 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
US7202260B2 (en) | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
US7238808B2 (en) | 2005-03-23 | 2007-07-03 | Hoffmann-La Roche Inc. | Acetylenyl-pyrazolo-pyrimidine derivatives |
WO2007107543A1 (en) | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
US7368446B2 (en) | 2004-05-24 | 2008-05-06 | Hoffmann-La Roche Inc. | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
JP2008518894A (ja) * | 2004-11-03 | 2008-06-05 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Vegf受容体キナーゼインヒビターとしてのアントラニルアミドピリジンウレア |
JP2008518893A (ja) * | 2004-11-03 | 2008-06-05 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 血管内皮成長因子(vegf)受容体キナーゼインヒビターとしてのニコチンアミドピリジンウレア |
EP1944026A2 (en) | 2002-05-16 | 2008-07-16 | Novartis AG | Use of EDG receptor binding agents in cancer |
WO2008093677A1 (ja) | 2007-01-29 | 2008-08-07 | Santen Pharmaceutical Co., Ltd. | 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体 |
EP1975166A1 (en) * | 2007-03-30 | 2008-10-01 | Bayer Schering Pharma AG | Synthesis of anthranilamides |
US7459563B2 (en) | 2004-11-05 | 2008-12-02 | Hoffmann-La Roche Inc. | Process for the preparation of isonicotinic acid derivatives |
EP2022498A2 (en) | 2005-11-21 | 2009-02-11 | Novartis AG | Neuroendocrine tumour treatment |
US7504404B2 (en) | 2005-09-27 | 2009-03-17 | Hoffmann-La Roche Inc. | Compounds as metabotropic glutamate receptor antagonists |
US7544703B2 (en) | 2004-02-17 | 2009-06-09 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein |
US7572794B2 (en) | 2004-11-03 | 2009-08-11 | Bayer Schering Pharma Ag | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
WO2010022725A1 (en) | 2008-08-27 | 2010-03-04 | Leo Pharma A/S | Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
WO2010043050A1 (en) | 2008-10-16 | 2010-04-22 | Celator Pharmaceuticals Corporation | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
WO2010071794A1 (en) | 2008-12-18 | 2010-06-24 | Novartis Ag | New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic |
WO2010080455A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | New salts |
WO2010080409A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid |
EP2210643A2 (en) | 2001-07-19 | 2010-07-28 | Novartis AG | Combinations comprising epothilones and pharmaceutical uses thereof |
WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
EP2253319A1 (en) | 2001-05-16 | 2010-11-24 | Novartis AG | Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent. |
WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
EP2269603A1 (en) | 2001-02-19 | 2011-01-05 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
EP2270008A1 (en) | 2005-05-20 | 2011-01-05 | Novartis AG | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors |
EP2272511A1 (en) | 2006-05-09 | 2011-01-12 | Novartis AG | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
WO2011015652A1 (en) | 2009-08-07 | 2011-02-10 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators |
WO2011018454A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
WO2011020861A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
WO2011022439A1 (en) | 2009-08-17 | 2011-02-24 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
US7897774B2 (en) | 2005-03-03 | 2011-03-01 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having quinolylalkylthio group |
WO2011023677A1 (en) | 2009-08-26 | 2011-03-03 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
US7906511B2 (en) | 2005-03-31 | 2011-03-15 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having pyrimidinylalkylthio group |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
WO2011029915A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
EP2308855A1 (en) | 2002-03-15 | 2011-04-13 | Novartis AG | 2,4-Diaminopyrimidine derivatives |
WO2011054828A1 (en) | 2009-11-04 | 2011-05-12 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
WO2011064211A1 (en) | 2009-11-25 | 2011-06-03 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
WO2011070030A1 (en) | 2009-12-08 | 2011-06-16 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2011076786A1 (en) | 2009-12-22 | 2011-06-30 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
US7989462B2 (en) | 2003-07-03 | 2011-08-02 | Myrexis, Inc. | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
EP2359818A1 (en) | 2007-02-15 | 2011-08-24 | Novartis AG | Combination of LBH589 with HSP 90 inhibitors for treating cancer |
WO2011157793A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
WO2011157787A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
EP2409969A1 (en) | 2004-06-24 | 2012-01-25 | Novartis AG | Pyrimidine urea derivatives as kinase inhibitors |
US8106190B2 (en) * | 2005-11-30 | 2012-01-31 | Astellas Pharma Inc. | 2-aminobenzamide derivatives |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012066095A1 (en) | 2010-11-19 | 2012-05-24 | Novartis Ag | Crystalline form of an inhibitor of mdm2/4 and p53 interaction |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
WO2012120469A1 (en) | 2011-03-08 | 2012-09-13 | Novartis Ag | Fluorophenyl bicyclic heteroaryl compounds |
WO2012149413A1 (en) | 2011-04-28 | 2012-11-01 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
WO2012168884A1 (en) | 2011-06-09 | 2012-12-13 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
EP2591775A1 (en) | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
WO2013096049A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096059A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096055A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096051A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096060A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
EP2628726A1 (en) | 2008-03-26 | 2013-08-21 | Novartis AG | Hydroxamate-based inhibitors of deacetylases b |
US8541442B2 (en) | 2009-02-04 | 2013-09-24 | Janssen Pharmaceutica N.V. | Indole derivatives as anticancer agents |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
US8853406B2 (en) | 2007-08-06 | 2014-10-07 | Janssen Pharmaceutica Nv | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53 |
WO2015022662A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
WO2016016822A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
EP3064502A1 (en) | 2012-01-26 | 2016-09-07 | Novartis AG | Imidazopyrrolidinone compounds |
US9725427B2 (en) | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
WO2019077037A1 (en) | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY |
WO2019119486A1 (zh) | 2017-12-21 | 2019-06-27 | 中国科学院合肥物质科学研究院 | 一类嘧啶类衍生物激酶抑制剂 |
EP3797765A1 (en) | 2006-06-27 | 2021-03-31 | Novartis AG | S1p receptor modulators for treating multiple sclerosis |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7427390B2 (en) * | 2004-03-10 | 2008-09-23 | Schering Ag | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy |
DE102004011720B4 (de) * | 2004-03-10 | 2008-04-03 | Bayer Schering Pharma Aktiengesellschaft | Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie |
DE102004039876A1 (de) * | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
JP5156378B2 (ja) | 2004-09-22 | 2013-03-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | MDM2とp53の間の相互作用の阻害剤 |
US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
JP5162574B2 (ja) * | 2006-03-22 | 2013-03-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Mdm2及びp53間の相互作用のインヒビターとしての環式アルキルアミン誘導体 |
WO2008077809A1 (en) * | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Process for the manufacture of 7-oxa-bicyclo derivatives |
CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
KR102061353B1 (ko) | 2010-09-10 | 2020-01-02 | 에피자임, 인코포레이티드 | 인간 ezh2의 억제제 및 이의 사용 방법 |
EP2681216B1 (en) | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
CN102603729A (zh) * | 2012-01-12 | 2012-07-25 | 贵州大学 | N-(2-(取代苯并噻唑-2-氨基甲酰基)-取代苯基)吡啶甲酰胺类衍生物 |
LT3184523T (lt) | 2012-04-13 | 2020-02-10 | Epizyme Inc | N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui |
TWI588131B (zh) | 2012-10-15 | 2017-06-21 | 雅酶股份有限公司 | 經取代苯化合物 |
CN103130696B (zh) * | 2013-03-21 | 2014-06-11 | 山东大学 | 邻氨基苯甲酰胺类化合物及其制备方法与应用 |
CN103405434A (zh) * | 2013-08-22 | 2013-11-27 | 中国药科大学 | Vegfr-2抑制剂及其用途 |
PL3057962T3 (pl) | 2013-10-16 | 2024-01-29 | Epizyme, Inc. | Postać soli chlorowodorku do inhibicji ezh2 |
CN104163794A (zh) * | 2013-10-17 | 2014-11-26 | 中国药科大学 | 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途 |
CA3166630A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
WO2022222890A1 (en) * | 2021-04-19 | 2022-10-27 | Shanghai Yao Yuan Biotechnology Co., Ltd. | Benzothiazole and quinoline derivatives for use in treating kawasaki disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3409668A (en) * | 1964-11-07 | 1968-11-05 | Palazzo Giuseppe | Substituted anthranilamides and process for the preparation thereof |
DE2652144A1 (de) * | 1976-11-16 | 1978-05-18 | Merck Patent Gmbh | Neue chinazolindione |
DE3406416A1 (de) * | 1983-02-28 | 1984-08-30 | American Cyanamid Co., Wayne, N.J. | N-((omega)-(1h-imidazol-l-yl)-alkyl)-arylamide |
EP0564356A1 (fr) * | 1992-04-01 | 1993-10-06 | Fournier Industrie Et Sante | Dérivés de 4-phénylaminométhylimidazole, procédé de préparation, antagonistes des récepteurs angiotensin II et leur application en thérapeutique |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3226394A (en) * | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
JPS5744672B2 (US07122547-20061017-C00163.png) | 1974-05-24 | 1982-09-22 | ||
US4568687A (en) * | 1983-02-28 | 1986-02-04 | American Cyanamid Company | N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions |
CA2155662A1 (en) * | 1993-12-27 | 1995-07-06 | Fumihiro Ozaki | Anthranilic acid derivative |
WO1997034895A1 (de) * | 1996-03-15 | 1997-09-25 | Novartis Ag | NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
-
1999
- 1999-09-11 UA UA2001063917A patent/UA71587C2/uk unknown
- 1999-11-09 KR KR1020017005800A patent/KR100777476B1/ko not_active IP Right Cessation
- 1999-11-09 BR BR9915553-2A patent/BR9915553A/pt not_active Application Discontinuation
- 1999-11-09 EE EEP200100258A patent/EE200100258A/xx unknown
- 1999-11-09 PL PL99348349A patent/PL348349A1/xx not_active Application Discontinuation
- 1999-11-09 KR KR1020077015852A patent/KR100855396B1/ko not_active IP Right Cessation
- 1999-11-09 EA EA200100524A patent/EA004701B1/ru not_active IP Right Cessation
- 1999-11-09 EP EP99953967A patent/EP1129074A2/de not_active Withdrawn
- 1999-11-09 CA CA002350208A patent/CA2350208A1/en not_active Abandoned
- 1999-11-09 TR TR2001/01307T patent/TR200101307T2/xx unknown
- 1999-11-09 SK SK607-2001A patent/SK6072001A3/sk unknown
- 1999-11-09 YU YU31801A patent/YU31801A/sh unknown
- 1999-11-09 HU HU0104425A patent/HUP0104425A3/hu unknown
- 1999-11-09 NZ NZ511413A patent/NZ511413A/en unknown
- 1999-11-09 AU AU10454/00A patent/AU771180B2/en not_active Ceased
- 1999-11-09 US US09/831,506 patent/US7122547B1/en not_active Expired - Fee Related
- 1999-11-09 CN CNB998130788A patent/CN1151133C/zh not_active Expired - Fee Related
- 1999-11-09 JP JP2000580999A patent/JP2002529452A/ja not_active Withdrawn
- 1999-11-09 WO PCT/EP1999/008478 patent/WO2000027819A2/de not_active Application Discontinuation
- 1999-11-09 CZ CZ20011631A patent/CZ20011631A3/cs unknown
-
2001
- 2001-05-07 NO NO20012245A patent/NO320647B1/no unknown
- 2001-05-25 HR HR20010402A patent/HRP20010402A2/hr not_active Application Discontinuation
- 2001-06-11 BG BG105588A patent/BG65371B1/bg unknown
-
2002
- 2002-05-14 HK HK02103628A patent/HK1041882A1/xx not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3409668A (en) * | 1964-11-07 | 1968-11-05 | Palazzo Giuseppe | Substituted anthranilamides and process for the preparation thereof |
DE2652144A1 (de) * | 1976-11-16 | 1978-05-18 | Merck Patent Gmbh | Neue chinazolindione |
DE3406416A1 (de) * | 1983-02-28 | 1984-08-30 | American Cyanamid Co., Wayne, N.J. | N-((omega)-(1h-imidazol-l-yl)-alkyl)-arylamide |
EP0564356A1 (fr) * | 1992-04-01 | 1993-10-06 | Fournier Industrie Et Sante | Dérivés de 4-phénylaminométhylimidazole, procédé de préparation, antagonistes des récepteurs angiotensin II et leur application en thérapeutique |
Non-Patent Citations (4)
Title |
---|
CHEMICAL ABSTRACTS, vol. 85, no. 3, 19. Juli 1976 (1976-07-19) Columbus, Ohio, US; abstract no. 21433p, NODA, KANJI ET AL: "Quinazoline compounds" Seite 701; XP002135867 & JP 50 157383 A (HISAMITSU PHARMACEUTICAL CO., LTD., JAPAN) 19. Dezember 1975 (1975-12-19) * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US MONTGINOUL, C. ET AL: "Analgesic, anticonvulsant and anti-inflammatory activities of 1H,3H-quinazoline-2,4-diones" retrieved from STN Database accession no. 110:165551h XP002135868 & ANN. PHARM. FR. (1989), 46(4), 223-32, * |
HARDTMANN, GOETZ E. ET AL: "Chemistry of 2H-3,1-benzoxazine-2,4(1H)-dione (isatoic anhydrides). 1. Synthesis of N-substituted 2H-3,1-benzoxazine-2,4(1H)-diones" JOURNAL OF HETEROCYCLIC CHEMISTRY., Bd. 12, Nr. 3, 1975, Seiten 565-572, XP002135866 HETEROCORPORATION. PROVO., US ISSN: 0022-152X * |
PASTOR, G. ET AL: "Synthesis of new 1H,3H-quinazoline-2,4-diones" BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE., Bd. 5-6, Nr. 2, 1975, Seiten 1331-1338, XP002135865 SOCIETE FRANCAISE DE CHIMIE. PARIS., FR ISSN: 0037-8968 * |
Cited By (224)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129245B2 (en) * | 1998-12-23 | 2006-10-31 | Eli Lilly And Company | Aromatic amides |
WO2001085719A1 (de) * | 2000-05-09 | 2001-11-15 | Schering Aktiengesellschaft | Ortho substituierte anthranilsäureamide und deren verwendung als arzneimittel |
WO2001085671A2 (de) * | 2000-05-09 | 2001-11-15 | Schering Aktiengesellschaft | Anthranylamide und deren verwendung als arzneimittel |
US6818661B2 (en) * | 2000-05-09 | 2004-11-16 | Novartis Ag | Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitors |
WO2001085671A3 (de) * | 2000-05-09 | 2002-04-11 | Schering Ag | Anthranylamide und deren verwendung als arzneimittel |
US7012081B2 (en) | 2000-05-09 | 2006-03-14 | Schering Ag | Anthranyl amides and their use as medicaments |
US7081468B2 (en) | 2000-05-09 | 2006-07-25 | Schering Ag | Ortho-substituted anthranilic acid amides and their use as medicaments |
US7479491B2 (en) * | 2000-05-09 | 2009-01-20 | Novartis Ag | Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors |
US6963000B2 (en) | 2000-06-21 | 2005-11-08 | Hoffman-La Roche Inc. | Benzothiazole derivatives with activity as adenosine receptor ligands |
US7317007B2 (en) | 2000-06-21 | 2008-01-08 | Hoffmann-La Roche Inc. | Benzothiazole derivatives with activity as adenosine receptor ligands |
WO2001097786A3 (en) * | 2000-06-21 | 2002-12-12 | Hoffmann La Roche | Benzothiazole derivatives |
US6835732B2 (en) | 2000-06-21 | 2004-12-28 | Hoffman-La Roche Inc. | Benzothiazole derivatives with activity as adenosine receptor ligands |
WO2001097786A2 (en) * | 2000-06-21 | 2001-12-27 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
US6521754B2 (en) | 2000-06-21 | 2003-02-18 | Hoffman-La Roche Inc. | Benzothiazole derivatives with activity as adenosine receptor ligands |
AU2001281817B2 (en) * | 2000-06-21 | 2005-11-24 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
WO2002046181A3 (en) * | 2000-12-07 | 2002-12-27 | Cv Therapeutics Inc | Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
AU2002225978B2 (en) * | 2000-12-07 | 2005-08-11 | Gilead Palo Alto, Inc. | ABCA-1 elevating compounds against coronary artery disease or atherosclerosis |
US6548548B2 (en) | 2000-12-07 | 2003-04-15 | Cv Therapeutics, Inc. | ABCA-1 elevating compounds |
WO2002046181A2 (en) * | 2000-12-07 | 2002-06-13 | Cv Therapeutics, Inc. | Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
WO2002066470A1 (en) * | 2001-01-12 | 2002-08-29 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
EP1798230A1 (en) * | 2001-01-12 | 2007-06-20 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7101868B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US7514564B2 (en) | 2001-01-12 | 2009-04-07 | Amgen Inc. | Substituted amine derivatives and methods of use |
CN1313464C (zh) * | 2001-01-12 | 2007-05-02 | 安姆根有限公司 | 取代的烷基胺衍生物、其制备方法、含其的组合物及其用途 |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
WO2002068406A3 (en) * | 2001-01-12 | 2003-04-24 | Amgen Inc | Substituted amine derivatives and their use for the treatment of angiogenesis |
EP2311808A1 (en) | 2001-01-12 | 2011-04-20 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
CZ303356B6 (cs) * | 2001-01-12 | 2012-08-08 | Amgen Inc. | Substituovaný alkylaminový derivát a farmaceutická kompozice s jeho obsahem |
US8058445B2 (en) | 2001-01-12 | 2011-11-15 | Amgen Inc. | Substituted pyridinecarboxamides for the treatment of cancer |
US8642624B2 (en) | 2001-01-12 | 2014-02-04 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
EP2311829A1 (en) | 2001-01-12 | 2011-04-20 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
WO2002055501A3 (en) * | 2001-01-12 | 2002-12-19 | Amgen Inc. | N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
BG66160B1 (bg) * | 2001-01-12 | 2011-09-30 | Amgen Inc. | Заместени алкиламинови производни и използването им |
US7687643B2 (en) | 2001-01-12 | 2010-03-30 | Amgen Inc. | Process for preparing 3,3-dimethylindolines |
EP3345602A1 (en) | 2001-02-19 | 2018-07-11 | Novartis AG | Rapamycin derivative for treating advanced solid tumours |
EP2783686A1 (en) | 2001-02-19 | 2014-10-01 | Novartis AG | Combination of a rapamycin derivative and letrozole for treating breast cancer |
EP3406249A1 (en) | 2001-02-19 | 2018-11-28 | Novartis AG | Treatment of breast tumors with a rapamycin derivative in combination with an aromatase inhibitor |
EP3351246A1 (en) | 2001-02-19 | 2018-07-25 | Novartis AG | Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis |
EP3342411A1 (en) | 2001-02-19 | 2018-07-04 | Novartis AG | Rapamycin derivative for treating pancreas cancer |
EP2762140A1 (en) | 2001-02-19 | 2014-08-06 | Novartis AG | Treatment of solid brain tumours with a rapamycin derivative |
EP2269603A1 (en) | 2001-02-19 | 2011-01-05 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
EP2269604A1 (en) | 2001-02-19 | 2011-01-05 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
EP2764865A2 (en) | 2001-02-19 | 2014-08-13 | Novartis AG | Cancer treatment |
US6864255B2 (en) | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
WO2003000678A1 (de) * | 2001-05-08 | 2003-01-03 | Schering Aktiengesellschaft | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel |
DE10123573A1 (de) * | 2001-05-08 | 2002-11-28 | Schering Ag | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel |
WO2002090352A2 (de) * | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren |
US7429592B2 (en) | 2001-05-08 | 2008-09-30 | Schering Aktienegesellschaft | Cyanoanthranilamide derivatives and the use thereof as medicaments |
DE10123587B4 (de) * | 2001-05-08 | 2005-04-07 | Schering Ag | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel |
JP2004528379A (ja) * | 2001-05-08 | 2004-09-16 | シエーリング アクチエンゲゼルシャフト | Vegfr−2およびvegfr−3インヒビターとしての選択的アントラニルアミドピリジンアミド |
WO2002090349A1 (de) * | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | N-oxidanthranylamid-derivate und deren verwendung als arzneimittel |
DE10123587A1 (de) * | 2001-05-08 | 2002-11-21 | Schering Ag | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel |
DE10123573B4 (de) * | 2001-05-08 | 2005-06-02 | Schering Ag | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel |
WO2002090352A3 (de) * | 2001-05-08 | 2003-05-01 | Schering Ag | Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren |
US7459470B2 (en) | 2001-05-08 | 2008-12-02 | Schering Ag | N-oxide anthranylamide derivatives and their use as medicaments |
EP2253319A1 (en) | 2001-05-16 | 2010-11-24 | Novartis AG | Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent. |
US7199147B2 (en) | 2001-06-12 | 2007-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Rho kinase inhibitors |
WO2002100833A1 (fr) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
JPWO2002100833A1 (ja) * | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Rhoキナーゼ阻害剤 |
EP2210643A2 (en) | 2001-07-19 | 2010-07-28 | Novartis AG | Combinations comprising epothilones and pharmaceutical uses thereof |
US7132438B2 (en) | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
US7635774B2 (en) | 2001-10-09 | 2009-12-22 | Amgen Inc. | Benzimidazole derivatives |
CN1300113C (zh) * | 2001-11-08 | 2007-02-14 | 诺瓦提斯公司 | 邻氨基苯甲酰胺和其作为vegf受体酪氨酸激酶抑制剂的用途 |
EP2308855A1 (en) | 2002-03-15 | 2011-04-13 | Novartis AG | 2,4-Diaminopyrimidine derivatives |
EP1955696A2 (en) | 2002-05-16 | 2008-08-13 | Novartis AG | Use of EDG receptor binding agents in cancer |
EP1944026A2 (en) | 2002-05-16 | 2008-07-16 | Novartis AG | Use of EDG receptor binding agents in cancer |
AU2003256481B2 (en) * | 2002-07-09 | 2007-08-09 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
JP2006502112A (ja) * | 2002-07-09 | 2006-01-19 | アムジエン・インコーポレーテツド | 置換アントラニルアミド誘導体および使用方法 |
WO2004005279A2 (en) * | 2002-07-09 | 2004-01-15 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
WO2004005279A3 (en) * | 2002-07-09 | 2004-03-11 | Amgen Inc | Substituted anthranilic amide derivatives and methods of use |
WO2004007458A1 (en) | 2002-07-17 | 2004-01-22 | Amgen Inc. | Substituted 2-alkylamine nicotinic amide derivatives and use there of |
WO2004007481A2 (en) * | 2002-07-17 | 2004-01-22 | Amgen Inc. | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
WO2004007481A3 (en) * | 2002-07-17 | 2004-02-19 | Amgen Inc | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
US7094789B2 (en) | 2002-07-22 | 2006-08-22 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivatives |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
DE10235690A1 (de) * | 2002-07-31 | 2004-02-19 | Schering Ag | VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide |
EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
JP2005538123A (ja) * | 2002-08-07 | 2005-12-15 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | アシルアミノ−置換複素芳香族化合物および医薬としてのそれらの使用 |
JP4778230B2 (ja) * | 2002-08-07 | 2011-09-21 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | アシルアミノ−置換複素芳香族化合物および医薬としてのそれらの使用 |
WO2004014369A1 (en) * | 2002-08-07 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
US7365070B2 (en) | 2002-12-04 | 2008-04-29 | Ore Pharmaceuticals Inc. | Modulators of melanocortin receptor |
WO2004050610A2 (en) * | 2002-12-04 | 2004-06-17 | Gene Logic Inc. | Modulators of melanocortin receptor |
US7790719B2 (en) | 2002-12-04 | 2010-09-07 | Ore Pharmaceuticals, Inc. | Modulators of melanocortin receptor |
WO2004050610A3 (en) * | 2002-12-04 | 2004-08-26 | Millennium Pharm Inc | Modulators of melanocortin receptor |
US7696225B2 (en) | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
US6949563B2 (en) | 2003-01-06 | 2005-09-27 | Graham Michael Wynne | (2-carboxamido)(3-amino)thiophene compounds |
WO2004063330A2 (en) | 2003-01-06 | 2004-07-29 | Osi Pharmaceuticals, Inc. | (2-carboxamido) (3-amino) thiophene compounds |
US7087761B2 (en) | 2003-01-07 | 2006-08-08 | Hoffmann-La Roche Inc. | Cyclization process for substituted benzothiazole derivatives |
WO2004069792A3 (en) * | 2003-02-03 | 2005-01-20 | Janssen Pharmaceutica Nv | Quinoline-derived amide modulators of vanilloid vr1 receptor |
EP2308848A1 (en) * | 2003-02-03 | 2011-04-13 | Janssen Pharmaceutica NV | Quinoline-derived amide modulators of vanilloid VR1 receptor |
US8394828B2 (en) | 2003-02-03 | 2013-03-12 | Janssen Pharmaceutica, Nv | Quinoline-derived amide modulators of vanilloid VR1 receptor |
WO2004072069A1 (en) * | 2003-02-14 | 2004-08-26 | Glaxo Group Limited | Carboxamide derivatives |
US7531558B2 (en) | 2003-02-14 | 2009-05-12 | Glaxo Group Limited | Carboxamide derivatives |
WO2004078723A1 (ja) | 2003-03-07 | 2004-09-16 | Santen Pharmaceutical Co. Ltd. | 4-ピリジルアルキルチオ基を置換基として有する新規化合物 |
US8518973B2 (en) | 2003-03-07 | 2013-08-27 | Santen Pharmaceutical Co., Ltd. | Compounds having 4-pyridylalkylthio group as a substituent |
US8207194B2 (en) | 2003-03-07 | 2012-06-26 | Santen Pharmaceutical Co., Ltd. | Compounds having a 4-pyridylalkylthio group as a substituent |
EP2527326A1 (en) | 2003-03-07 | 2012-11-28 | Santen Pharmaceutical Co., Ltd | Novel compounds having 4-pyridylalkylthio group as substituent |
US7534802B2 (en) | 2003-03-07 | 2009-05-19 | Santen Pharmaceutical Co., Ltd. | Compounds having 4-pyridylalkylthio group as substituent |
WO2004103306A2 (en) | 2003-05-19 | 2004-12-02 | Irm Llc | Immunosuppressant compounds and compositions |
WO2005000833A1 (en) | 2003-05-19 | 2005-01-06 | Irm, Llc | Immunosuppressant compounds and compositions |
EP3272736A1 (en) | 2003-05-19 | 2018-01-24 | Novartis Ag | Immunosuppressant compounds and compositions |
EP2644195A1 (en) | 2003-05-19 | 2013-10-02 | Irm Llc | Immunosuppressant Compounds and Compositions |
EP2514743A1 (en) | 2003-05-19 | 2012-10-24 | Irm Llc | Immunosuppressant Compounds and Compositions |
WO2004108133A2 (en) * | 2003-06-05 | 2004-12-16 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
WO2004108133A3 (en) * | 2003-06-05 | 2005-03-31 | Vertex Pharma | Modulators of vr1 receptor |
JP2006526660A (ja) * | 2003-06-05 | 2006-11-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Vr1レセプターのモジュレーター |
WO2004111005A1 (de) * | 2003-06-13 | 2004-12-23 | Schering Aktiengesellschaft | Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyridone |
US7202260B2 (en) | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
US7989462B2 (en) | 2003-07-03 | 2011-08-02 | Myrexis, Inc. | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2005004864A1 (en) * | 2003-07-11 | 2005-01-20 | Merck Patent Gmbh | Benzimidazole derivatives as raf kinase inhibitors |
US7691886B2 (en) | 2003-07-11 | 2010-04-06 | Merck Patent Gmbh | Benzimidazole derivatives as raf kinase inhibitors |
WO2005047273A1 (en) * | 2003-11-14 | 2005-05-26 | Novartis Ag | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors |
WO2005054179A2 (en) | 2003-12-03 | 2005-06-16 | Leo Pharma A/S | Hydroxamic acid esters and pharmaceutical use thereof |
US7544703B2 (en) | 2004-02-17 | 2009-06-09 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein |
WO2005085202A1 (de) * | 2004-02-26 | 2005-09-15 | Merck Patent Gmbh | Pyridinamid-derivate als kinase-inhibitoren |
EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
WO2005085188A3 (en) * | 2004-03-02 | 2006-06-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
US7368446B2 (en) | 2004-05-24 | 2008-05-06 | Hoffmann-La Roche Inc. | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
EP2409969A1 (en) | 2004-06-24 | 2012-01-25 | Novartis AG | Pyrimidine urea derivatives as kinase inhibitors |
EP2418205A1 (en) | 2004-06-24 | 2012-02-15 | Novartis AG | Pyrimidine urea derivatives as kinase inhibitors |
WO2006047574A1 (en) | 2004-10-26 | 2006-05-04 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-amino) thiophene compounds |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
JP2008518893A (ja) * | 2004-11-03 | 2008-06-05 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 血管内皮成長因子(vegf)受容体キナーゼインヒビターとしてのニコチンアミドピリジンウレア |
JP2008518894A (ja) * | 2004-11-03 | 2008-06-05 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Vegf受容体キナーゼインヒビターとしてのアントラニルアミドピリジンウレア |
US7572794B2 (en) | 2004-11-03 | 2009-08-11 | Bayer Schering Pharma Ag | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
US7902229B2 (en) | 2004-11-03 | 2011-03-08 | Bayer Schering Pharma Ag | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
US7459563B2 (en) | 2004-11-05 | 2008-12-02 | Hoffmann-La Roche Inc. | Process for the preparation of isonicotinic acid derivatives |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
US7897774B2 (en) | 2005-03-03 | 2011-03-01 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having quinolylalkylthio group |
US8063048B2 (en) | 2005-03-23 | 2011-11-22 | Hoffmann-La Roche Inc. | Acetylenyl-pyrazolo-pyrimidine derivatives |
US7718661B2 (en) | 2005-03-23 | 2010-05-18 | Hoffmann-La Roche Inc. | Acetylenyl-pyrazolo-pyrimidine derivatives |
US7238808B2 (en) | 2005-03-23 | 2007-07-03 | Hoffmann-La Roche Inc. | Acetylenyl-pyrazolo-pyrimidine derivatives |
US7446113B2 (en) | 2005-03-23 | 2008-11-04 | Hoffman-La Roche Inc. | Acetylenyl-pyrazolo-pyrimidine derivatives |
US7906511B2 (en) | 2005-03-31 | 2011-03-15 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having pyrimidinylalkylthio group |
US8507485B2 (en) | 2005-03-31 | 2013-08-13 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having pyrimidinylalkylthio group |
EP2292617A1 (en) | 2005-05-20 | 2011-03-09 | Novartis AG | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors |
EP2270008A1 (en) | 2005-05-20 | 2011-01-05 | Novartis AG | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors |
US8093263B2 (en) | 2005-09-27 | 2012-01-10 | Hoffmann-La Roche Inc. | Substituted pyrazolo [1,5-a] pyrimidines as metabotropic glutamate antagonists |
WO2007038459A2 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
US7504404B2 (en) | 2005-09-27 | 2009-03-17 | Hoffmann-La Roche Inc. | Compounds as metabotropic glutamate receptor antagonists |
US8349844B2 (en) | 2005-09-27 | 2013-01-08 | Hoffmann-La Roche Inc. | Substituted pyrazolo [1,5-A] pyrimidines as metabotropic glutamate antagonists |
EP2022498A2 (en) | 2005-11-21 | 2009-02-11 | Novartis AG | Neuroendocrine tumour treatment |
EP2275103A2 (en) | 2005-11-21 | 2011-01-19 | Novartis AG | mTOR inhibitors in the treatment of endocrine tumors |
US8106190B2 (en) * | 2005-11-30 | 2012-01-31 | Astellas Pharma Inc. | 2-aminobenzamide derivatives |
US8232298B2 (en) | 2006-03-22 | 2012-07-31 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between MDM2 and P53 |
WO2007107543A1 (en) | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
EP2591775A1 (en) | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
EP2272511A1 (en) | 2006-05-09 | 2011-01-12 | Novartis AG | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
EP3797765A1 (en) | 2006-06-27 | 2021-03-31 | Novartis AG | S1p receptor modulators for treating multiple sclerosis |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
US8063034B2 (en) | 2007-01-29 | 2011-11-22 | Santen Pharmaceutical Co., Ltd. | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity |
WO2008093677A1 (ja) | 2007-01-29 | 2008-08-07 | Santen Pharmaceutical Co., Ltd. | 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体 |
EP2359818A1 (en) | 2007-02-15 | 2011-08-24 | Novartis AG | Combination of LBH589 with HSP 90 inhibitors for treating cancer |
EP2491923A2 (en) | 2007-02-15 | 2012-08-29 | Novartis AG | Combinations of therapeutic agents for treating cancer |
EP1975166A1 (en) * | 2007-03-30 | 2008-10-01 | Bayer Schering Pharma AG | Synthesis of anthranilamides |
WO2008119569A1 (en) * | 2007-03-30 | 2008-10-09 | Bayer Schering Pharma Aktiengesellschaft | Synthesis of anthranilamides |
US8853406B2 (en) | 2007-08-06 | 2014-10-07 | Janssen Pharmaceutica Nv | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53 |
EP2628726A1 (en) | 2008-03-26 | 2013-08-21 | Novartis AG | Hydroxamate-based inhibitors of deacetylases b |
WO2010022725A1 (en) | 2008-08-27 | 2010-03-04 | Leo Pharma A/S | Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
WO2010043050A1 (en) | 2008-10-16 | 2010-04-22 | Celator Pharmaceuticals Corporation | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
WO2010080409A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid |
WO2010080455A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | New salts |
WO2010071794A1 (en) | 2008-12-18 | 2010-06-24 | Novartis Ag | New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic |
WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
US8541442B2 (en) | 2009-02-04 | 2013-09-24 | Janssen Pharmaceutica N.V. | Indole derivatives as anticancer agents |
WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
WO2011015652A1 (en) | 2009-08-07 | 2011-02-10 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators |
WO2011018454A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
WO2011022439A1 (en) | 2009-08-17 | 2011-02-24 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
WO2011020861A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
WO2011023677A1 (en) | 2009-08-26 | 2011-03-03 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
WO2011029915A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
WO2011054828A1 (en) | 2009-11-04 | 2011-05-12 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
WO2011064211A1 (en) | 2009-11-25 | 2011-06-03 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
WO2011070030A1 (en) | 2009-12-08 | 2011-06-16 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2011076786A1 (en) | 2009-12-22 | 2011-06-30 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
WO2011157793A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
WO2011157787A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012066095A1 (en) | 2010-11-19 | 2012-05-24 | Novartis Ag | Crystalline form of an inhibitor of mdm2/4 and p53 interaction |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
WO2012120469A1 (en) | 2011-03-08 | 2012-09-13 | Novartis Ag | Fluorophenyl bicyclic heteroaryl compounds |
WO2012149413A1 (en) | 2011-04-28 | 2012-11-01 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012168884A1 (en) | 2011-06-09 | 2012-12-13 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
WO2013096059A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096049A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096055A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096051A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096060A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
EP3064502A1 (en) | 2012-01-26 | 2016-09-07 | Novartis AG | Imidazopyrrolidinone compounds |
EP3272754A1 (en) | 2012-01-26 | 2018-01-24 | Novartis AG | Imidazopyrrolidinone compounds |
US9725427B2 (en) | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
US10844026B2 (en) | 2012-03-16 | 2020-11-24 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of riluzole and their method of use |
US11440893B2 (en) | 2012-03-16 | 2022-09-13 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of riluzole and their method of use |
US10562870B2 (en) | 2012-03-16 | 2020-02-18 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of riluzole and their method of use |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
EP3964513A1 (en) | 2012-04-03 | 2022-03-09 | Novartis AG | Combination products with tyrosine kinase inhibitors and their use |
WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022662A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
WO2016016822A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
WO2019077037A1 (en) | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY |
WO2019119486A1 (zh) | 2017-12-21 | 2019-06-27 | 中国科学院合肥物质科学研究院 | 一类嘧啶类衍生物激酶抑制剂 |
US11602534B2 (en) | 2017-12-21 | 2023-03-14 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Pyrimidine derivative kinase inhibitors |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
Also Published As
Publication number | Publication date |
---|---|
NO20012245L (no) | 2001-07-10 |
BG65371B1 (bg) | 2008-04-30 |
PL348349A1 (en) | 2002-05-20 |
YU31801A (sh) | 2003-12-31 |
HUP0104425A2 (hu) | 2002-03-28 |
KR100777476B1 (ko) | 2007-11-16 |
EA200100524A1 (ru) | 2002-02-28 |
US7122547B1 (en) | 2006-10-17 |
KR100855396B1 (ko) | 2008-08-29 |
TR200101307T2 (tr) | 2002-05-21 |
EE200100258A (et) | 2002-12-16 |
NZ511413A (en) | 2004-01-30 |
CA2350208A1 (en) | 2000-05-18 |
CN1325384A (zh) | 2001-12-05 |
CN1151133C (zh) | 2004-05-26 |
UA71587C2 (uk) | 2004-12-15 |
AU1045400A (en) | 2000-05-29 |
HRP20010402A2 (en) | 2003-10-31 |
NO320647B1 (no) | 2006-01-09 |
BR9915553A (pt) | 2001-08-14 |
KR20070087027A (ko) | 2007-08-27 |
EP1129074A2 (de) | 2001-09-05 |
AU771180B2 (en) | 2004-03-18 |
EA004701B1 (ru) | 2004-06-24 |
BG105588A (en) | 2002-04-30 |
HUP0104425A3 (en) | 2003-05-28 |
KR20010075689A (ko) | 2001-08-09 |
WO2000027819A3 (de) | 2000-08-17 |
HK1041882A1 (en) | 2002-07-26 |
CZ20011631A3 (cs) | 2001-10-17 |
NO20012245D0 (no) | 2001-05-07 |
SK6072001A3 (en) | 2002-01-07 |
JP2002529452A (ja) | 2002-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000027819A2 (de) | Anthranilsäureamide und deren verwendung als arzneimittel | |
EP1280776B1 (de) | Substituierte benzoesäureamide und deren verwendung zur hemmung von angiogenese | |
DE10023486C1 (de) | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel | |
WO2001085715A2 (de) | Aza- und polyazanthranylamide und deren verwendung als arzneimittel | |
WO2001085671A2 (de) | Anthranylamide und deren verwendung als arzneimittel | |
WO2001085691A1 (de) | Anthranylalkyl- und -cycloalkylamide und deren verwendung als vegf-rezeptorenhemmer | |
JP2002529452A5 (US07122547-20061017-C00163.png) | ||
EP1387838B1 (de) | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel | |
WO2002090349A1 (de) | N-oxidanthranylamid-derivate und deren verwendung als arzneimittel | |
DE19910396C2 (de) | Anthranilsäureamide und deren Verwendung als Arzneimittel | |
EP0068240B1 (de) | 2-Acylaminomethyl-1,4-benzodiazepin-Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DE10123573B4 (de) | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel | |
DE10123587B4 (de) | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel | |
DE10125295A1 (de) | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel (II) | |
DE10125293A1 (de) | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel (II) | |
MXPA01004692A (en) | Antrhranilic acid amides and the use thereof as medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-318/01 Country of ref document: YU Ref document number: 99813078.8 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2000 10454 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999953967 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 142618 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/00422/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 511413 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: A 2001 00481 Country of ref document: RO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6072001 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2350208 Country of ref document: CA Ref document number: 2350208 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017005800 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2000 580999 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-1631 Country of ref document: CZ Ref document number: 10454/00 Country of ref document: AU Ref document number: 2001/01307 Country of ref document: TR Ref document number: PA/a/2001/004692 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20010402A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/04673 Country of ref document: ZA Ref document number: 200104673 Country of ref document: ZA Ref document number: 200100524 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 1999 105588 Country of ref document: BG Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017005800 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999953967 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09831506 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-1631 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 10454/00 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017005800 Country of ref document: KR |